Product Description
IONIS-KRAS-2.5Rx is a Generation 2.5 antisense drug discovered by Ionis designed to directly target KRAS, one of the most frequently mutated genes in cancer. (Sourced from: https://ir.ionispharma.com/news-releases/news-release-details/ionis-earns-28-million-astrazeneca-new-drug-treat-cancer)
Mechanisms of Action: KRAS G12C Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| D8360C00001 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2019-01-08 |
12% |
2019-04-17 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |